Oppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00

Keros Therapeutics (NASDAQ:KROS) had its target price reduced by Oppenheimer from $63.00 to $23.00 in a research report report published on Thursday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other analysts have also issued research reports about the stock. Wells Fargo & Company lifted their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Scotiabank reduced their price objective on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a report on Friday, December 13th. Wedbush restated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Guggenheim cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Finally, William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.22.

Keros Therapeutics Trading Up 1.0 %

Shares of KROS opened at $10.52 on Thursday. The stock has a 50 day moving average of $38.65 and a 200 day moving average of $47.61. The company has a market capitalization of $426.17 million, a price-to-earnings ratio of -2.02 and a beta of 1.43. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.33) earnings per share. As a group, equities research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KROS. KBC Group NV boosted its position in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in Keros Therapeutics in the 3rd quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the 2nd quarter valued at $128,000. Finally, LMR Partners LLP purchased a new position in shares of Keros Therapeutics during the 3rd quarter valued at $213,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.